Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: A practice-based observational study

Journal of Bone and Mineral Metabolism

Volumn 29, Issue 1, 2011, Pages 88-95

  Takakuwa, Masayuki ^a   Iwamoto, Jun ^e   Konishi, Masahisa ^b   Zhou, Qi ^c   Itabashi, Koichi ^d  

^a Takakuwa Orthopaedic Nagayama Clinic   (Japan)

^b GE HEALTHCARE   (United Kingdom)

^c GE HEALTHCARE   (China)

^d EISAI CO LTD   (Japan)

^e NONE

Author keywords

Advanced hip assessment; Bone mineral density; Femoral neck; Geometry; Risedronate

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; RISEDRONIC ACID;

AGED; ARTICLE; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; GEOMETRY; HIGH RISK PATIENT; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK FACTOR; TREATMENT DURATION;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 79951681583     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-010-0196-x     Document Type: Article

References (28)

1. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10.1007/s001980050010 10663363 (Pubitemid 30099515)
2. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
3. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 10.1056/NEJM200102013440503 11172164 (Pubitemid 32107641)
4. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD004523
5. ZM Zhong JT Chen 2009 Anti-fracture efficacy of risedronic acid in men: a meta-analysis of randomized controlled trials Clin Drug Invest 29 349 357 1:CAS:528:DC%2BD1MXmtlait7o%3D 10.2165/00044011-200929050-00007
6. C Roux E Seeman R Eastell J Adachi RD Jackson D Felsenberg S Songcharoen R Rizzoli O Di Munno S Horlait D Valent NB Watts 2004 Efficacy of risedronate on clinical vertebral fractures within 6 months Curr Med Res Opin 20 433 439 1:CAS:528:DC%2BD2cXksVSis7g%3D 10.1185/030079903125003125 15119979 (Pubitemid 38525150)
7. JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer I Barton S Boonen 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 129 135 1:CAS:528:DC%2BD2cXhtFGjt78%3D 10.1007/s00223-003-0042-4 14648009 (Pubitemid 38263854)
8. JE Dunford K Thompson FP Coxon SP Luckman FM Hahn CD Poulter FH Ebetino MJ Rogers 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 235 342 1:CAS:528:DC%2BD3MXoslaluw%3D%3D 11160603
9. NIH Consensus Development Panel 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795 10.1001/jama.285.6.785
10. T Yoshikawa CH Turner M Peacock CW Slemenda CM Weaver D Teegarden P Markwardt DB Burr 1994 Geometric structure of the femoral neck measured using dual-energy-X-ray absorptiometry J Bone Miner Res 9 1053 1064 1:STN:280:DyaK2M%2FivVKhsA%3D%3D 10.1002/jbmr.5650090713 7942152 (Pubitemid 24191793)
11. M Shiraki M Fukunaga K Kushida H Kishimoto Y Taketani H Minaguchi T Inoue R Morita H Morii K Yamamoto Y Ohashi H Orimo 2003 A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group) Osteoporos Int 14 225 234 1:CAS:528:DC%2BD3sXlslOls7c%3D 12730746 (Pubitemid 40826236)
12. H Orimo Y Sugioka M Fukunaga Y Muto T Hotokebuchi I Gorai T Nakamura K Kushida H Tanaka T Ikai Y Oh-hashi 1998 Diagnostic criteria of primary osteoporosis J Bone Miner Metab 16 139 150 10.1007/s007740050038 (Pubitemid 28411037)
13. H Orimo Y Hayashi M Fukunaga T Sone S Fujiwara M Shiraki K Kushida S Miyamoto S Soen J Nishimura Y Oh-Hashi T Hosoi I Gorai H Tanaka T Igai H Kishimoto Osteoporosis Diagnostic Criteria Review Committee Japanese Society for Bone Mineral Research 2001 Diagnostic criteria for primary osteoporosis: year 2000 revision J Bone Miner Metab 19 331 337 1:STN:280:DC%2BD3MngvFGntw%3D%3D 10.1007/s007740170001 11685647 (Pubitemid 33041725)
14. Orimo H (2006) Japanese guideline for prevention and treatment of osteoporosis. Life Science, Tokyo (in Japanese)
15. M Fukunaga K Kushida H Kishimoto M Shiraki Y Taketani H Minaguchi T Inoue R Morita H Morii K Yamamoto Y Ohashi H Orimo 2002 A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial Osteoporos Int 13 971 979 1:CAS:528:DC%2BD38XptFGitrY%3D 10.1007/s001980200135 12459940 (Pubitemid 36050275)
16. H Kishimoto M Fukunaga K Kushida M Shiraki A Itabashi H Nawata T Nakamura H Ohta K Takaoka Y Ohashi 2006 Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen J Bone Miner Metab 24 405 413 1:CAS:528:DC%2BD28XoslCjsr8%3D 10.1007/s00774-006-0706-z 16937274 (Pubitemid 44306178)
17. TJ Beck AC Looker CB Ruff H Sievanen HW Wahner 2000 Structural trends in the aging femoral neck and proximal shaft; analysis of the third national health and nutrition examination survey dual-energy X-ray absorptiometry data J Bone Miner Res 15 2297 2304 1:STN:280:DC%2BD3M%2FpsF2mtA%3D%3D 10.1359/jbmr.2000.15. 12.2297 11127194
18. LJ Melton III TJ Beck S Amin S Khosla SJ Achenbach AL Oberg BL Riggs 2005 Contributions of bone density and structure to fracture risk assessment in men and women Osteoporos Int 16 460 467 10.1007/s00198-004-1820-1 15688123
19. J Takada TJ Beck K Iba T Yamashita 2007 Structural trends in the aging proximal femur in Japanese postmenopausal women Bone (NY) 41 97 102 (Pubitemid 46891904)
20. X Cheng H Barden JK Brown Q Zhou 2007 Comparison of femur structure measurements derived from DXA and QCT J Bone Miner Res 22 suppl 1 S420
21. C Muschitz L Milassin T Pirker R Waneck H Resch 2007 DXA and QCT geometric structural measurements of proximal femoral strength J Bone Miner Res 22 suppl 1 S303
22. KG Faulkner WK Wacker HS Barden C Simonelli PK Burke S Ragi L Del Rio 2006 Femur strength index predicts hip fracture independent of bone density and hip axis length Osteoporosis Int 17 593 599 1:STN:280:DC%2BD287msF2muw%3D%3D 10.1007/s00198-005-0019-4
23. P Szulc F Duboeuf AM Schott P Dargent-Molina PJ Meunier PD Delmas 2006 Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study Osteoporos Int 17 231 236 1:STN:280: DC%2BD287islWrug%3D%3D 10.1007/s00198-005-1980-7 15983728 (Pubitemid 43053586)
24. CA Mautalen EM Vega TA Einhorn 1996 Are the etiologies of cervical and trochanteric hip fractures different? Bone (NY) 18 (suppl) S133 S137
25. SL Greenspan TJ Beck NM Resnick R Bhattacharya RA Parker 2005 Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double blind, placebo controlled clinical trial J Bone Miner Res 20 1525 1532 1:CAS:528:DC%2BD2MXhtVOltrrK 10.1359/JBMR.050508 16059624 (Pubitemid 41243541)
26. SL Bonnick TJ Beck F Cosman MC Hochberg H Wang AE de Papp 2009 DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass Osteoporos Int 20 911 921 1:CAS:528: DC%2BD1MXls12kt70%3D 10.1007/s00198-008-0762-4 18830555
27. GJ van Londen S Perera KT Vujevich SM Sereika R Bhattacharya SL Greenspan 2008 Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women Bone (NY) 43 274 278
28. J Iwamoto Y Sato T Takeda H Matsumoto 2008 Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature Clin Interv Aging 3 483 489 18982918